{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-057911","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.263396+00:00","generated_at":"2026-06-27T03:38:37.026198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Atea reports Q4 net income of $117.1M on Roche revenue recognition; pivots COVID-19 pipeline to combo","bullets":["Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.","Phase 3 MORNINGSKY trial closed; COVID-19 program shifts to Phase 2 combination with a protease inhibitor in 2H 2022.","Initiated Phase 2 HCV combination trial of bemnifosbuvir and ruzasvir (in-licensed from Merck) in 2H 2022.","AT-752 Phase 2 dengue program expected to start 1H 2022 with results late 2022; cash $764.4M at Dec 31, 2021.","Roche collaboration terminated effective Feb 10, 2022; Atea regains full worldwide rights to bemnifosbuvir."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-057911","json":"https://secwatch.observer/filing/0001193125-22-057911.json","markdown":"https://secwatch.observer/filing/0001193125-22-057911.md","text":"https://secwatch.observer/filing/0001193125-22-057911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/0001193125-22-057911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/d279167d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:38:37.026198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}